Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition

Eike Gallmeier, Scott E. Kern

Research output: Contribution to journalShort survey

Abstract

The specific killing of cells impaired in BRCA2 function upon treatment with poly (ADP-ribose) polymerase (PARP) inhibitors has recently been reported by two groups. CAPAN1, which was not characterized in these reports, represents the only human cancer cell line harboring the frequent, naturally occurring BRCA2 6174delT frameshift mutation accompanied by loss of the second allele. The severe impact of this mutation on BRCA2 function has been extensively characterized. However, PARP inhibition by 3-aminobenzamide or NU1025 did not result in significant cell death in CAPAN1 cells. Our data raise concern about the uniformity of the specific cell killing of BRCA2-deficient cells upon PARP inhibition and therefore urge caution as to whether prior findings are fully generalizable for the specific treatment of human cancers harboring naturally occurring, inactivating forms of BRCA2 mutations.

Original languageEnglish (US)
Pages (from-to)703-706
Number of pages4
JournalCancer Biology and Therapy
Volume4
Issue number7
DOIs
StatePublished - Jul 2005

    Fingerprint

Keywords

  • BRCA2
  • Breast cancer
  • CAPAN1
  • PARP inhibition
  • Pancreatic cancer
  • Poly(ADP-ribose) polymerase
  • Selective cell killing

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this